Clinical Trials Logo

Smell Disorder clinical trials

View clinical trials related to Smell Disorder.

Filter by:

NCT ID: NCT06115291 Active, not recruiting - Clinical trials for Traumatic Brain Injury

Olfactory Training in Various Populations

Start date: February 13, 2020
Phase: N/A
Study type: Interventional

To date, there is no validated pharmacotherapy for olfactory disorders. Interestingly, olfactory training - the intentional exposure to odorants for the purposes of retraining the sense of smell - has shown success with as many as 28% of subjects over the course of 12 weeks.

NCT ID: NCT05760079 Withdrawn - Covid19 Clinical Trials

Lactoferrin for COVID-19-Induced Taste or Smell Abnormality

TSA
Start date: June 2022
Phase: N/A
Study type: Interventional

Common side effects of corona virus disease 2019 (COVID-19) include disruptions in taste and smell function, which may persist for prolonged periods of time following recovery and resolution of COVID-19 infection. These disruptions not only reduce the hedonic pleasure derived from eating, but may also be detrimental to quality of life and could pose additional health risks (malnutrition) among patients with chronic illness or those enduring long-term complications from their previous COVID-19 infection. Previous studies conducted among patients with cancer experiencing taste and smell abnormalities have indicated improvement in taste and smell function following daily lactoferrin supplementation. Lactoferrin is a natural transferrin protein that scavenges and chelates iron byproducts produced as a function of lipid oxidation in the oral cavity following inflammation, infection, or toxicity of chemosensory tissues. The purpose of this pilot investigation is to assess the feasibility and preliminary effectiveness of lactoferrin supplementation (750mg per day for 30 days) for the treatment of taste and smell disturbances following COVID-19 infection. Approximately 40 patients who experienced disruptions in taste and smell following infection with COVID-19 will be recruited. Participants will complete baseline assessments (questionnaires, blood draw) and will be given 90 lactoferrin tablets (provided by Jarrow Formulas) in order to take 3 tablets per day for 30 days.

NCT ID: NCT05104424 Not yet recruiting - Taste Disorders Clinical Trials

The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Taste Dysfunctions

COVID-19
Start date: December 26, 2021
Phase: Phase 1
Study type: Interventional

post covid-19 smell and taste dysfunction are common globally and affect the quality of life and also have phycological impact and anxiety, also affect on economy as the patients not able to do cooking or buy prepared foods and not eaten, also not able to enter the cooking room and prepare foods for themselves, also the risk of loss of smell the fire accidents because anosmia, many forms of smell dysfunction like anosmia ,hyposmia, and dysosmia ,Phantosmia , parosmia may occurred, the same taste disorders may has many forms like Dysgeusia, phantom taste perception, hypogeusia with dysgeusia. until now no definite treatments for post covid-19 smell and taste disorders , this study is novel study as quadruple therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation may suspect having promising results

NCT ID: NCT05038475 Enrolling by invitation - COVID-19 Clinical Trials

Clinical and Immunological Responses After SARS-CoV-2 Infection Causing COVID-19

Start date: May 1, 2020
Phase:
Study type: Observational

There are very few long-term studies that analyze the immune responses in patients recovered from COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main aim of this study is to analyze the clinical profile and immune responses of recovered COVID-19 patients in a representative cohort of people in the Umbria region of Italy. The participants had a history of testing positive for SARS-CoV-2 in March 2020 by Reverse Transcriptase- Quantitative Polymerase Chain Reaction (RT-qPCR). The participants were invited for voluntary participation in a seroprevalence study. This study analyzes longitudinally the presence of antibodies against SARS-CoV-2 by sequential serological tests at different time points using two FDA-approved Immunoassays. At the first serum sample collection, the participants were asked to provide information about their COVID-19 clinical history including clinical profile, co-morbidities, and treatment undertaken using a standardized questionnaire. Successive sequential serological assessments were conducted to understand the immune responses in these recovered patients. Moreover, stage two of the study involves, analysis of antibody titers in recovered vaccinated individuals and their follow-up.

NCT ID: NCT04868435 Completed - Smell Disorder Clinical Trials

Triggers for Post-Viral Parosmia

ParosmiaQ
Start date: November 3, 2020
Phase:
Study type: Observational

Background: Many people lose their sense of smell after they have had a cold, flu or sinus infection. Recovery (if at all) generally starts with a "parosmia" phase which means every-day smells become distorted and over-poweringly objectionable, and this can lead to malnutrition and depression. We do not know much about how or why parosmia happens, but there are key foods common to those who suffer from parosmia which seem to trigger the distortion. Parosmia and COVID-19 Loss of smell has recently been recognised as an official symptom of COVID-19, and we are starting to get reports of people who have recently had COVID-19 developing parosmia. The triggers seem to be similar to those of the common cold, flu or virus infections, but the journey between loss of smell and parosmia is different. Hypotheses 1. Triggers of distortion will be the same for all parosmics. 2. There may be additional trigger foods in different cultures. Questions 1. What are the trigger foods and beverages for parosmia? 2. Are there regional/cultural variations? 3. Does Covid-19 parosmia differ from "standard" post-viral parosmia? The overall aim of the project is to understand the mechanisms involved in parosmia. The approach is to identify foods and everyday aromas associated with parosmia and to determine whether they are the same across different continents/cultures/ethnic backgrounds, and whether Covid-19 parosmia is any different to non-Covid-19 parosmia. The questionnaire will ask about Covid-19 status, ethnic background, smell loss and parosmia, and the changes that occurred between smell loss and parosmia. The participants will then answer questions on up to 15 everyday smells, some of which our preliminary evidence shows are common triggers, and others which are not. The questionnaire will be globally distributed, for example through current collaborations in the UK, US, Germany, Iran, China, Japan and Brazil. It will be completed by participants who are currently experiencing parosmia. All participants will be asked to record any foods that they find distorted and provide a list of aromas which returned undistorted.

NCT ID: NCT04532632 Completed - Clinical trials for Coronavirus Infection

Taste and Smell Impairment in Critically Ill COVID-19 Patients

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

Evaluating the smell and taste perceptions of patients hospitalized in the intensive care unit with suspicion of Coronavirus disease-19 diagnosis with a survey study

NCT ID: NCT04466982 Recruiting - COVID19 Clinical Trials

Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection

ODYSSI
Start date: July 2, 2020
Phase:
Study type: Observational

This study is designed to investigate the acuity of olfactory dysfunction in COVID-19 positive patients in the United Kingdom. In particular defining severity with objective testing and determining if this has any predictive value on the outcome of the SARS CoV-2 infection. In addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive SARS CoV-2 diagnosis. It should also demonstrate the impact of olfactory dysfunction on patient Quality of Life (QOL).

NCT ID: NCT04253054 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Chinese Multi-provincial Cohort Study-Beijing Project

CMCS-Beijing
Start date: September 7, 2020
Phase:
Study type: Observational

The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.

NCT ID: NCT04194788 Completed - Clinical trials for Orthopedic Disorder of Spine

Olfaction Changes in Patients Undergoing Spine Surgery

Start date: April 29, 2021
Phase:
Study type: Observational

This observational prospective study evaluates perioperative olfaction alterations, comprising changes in threshold value, discrimination and identification, which occur in spine patients. The single group is subjected to a preoperative and a postoperative assessment.

NCT ID: NCT03990766 Completed - Viral Infection Clinical Trials

Smell Changes & Efficacy of Nasal Theophylline

SCENT
Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of nasal theophylline irrigation in treating smell loss related to a viral respiratory infection. Half the participants will undergo nasal theophylline irrigation treatment while the other half will undergo placebo nasal irrigation with saline alone. All participants will have their sense of smell tested before and after 6 weeks of treatment. All participants will also be regularly asked about any potential side effects related to treatment. In addition, the first 10 participants will have their blood drawn to measure their theophylline level after 1 week of starting treatment to ensure it is not abnormally elevated.